Martin Hoyle

9.5k total citations
69 papers, 2.3k citations indexed

About

Martin Hoyle is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Martin Hoyle has authored 69 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Martin Hoyle's work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Pharmaceutical Economics and Policy (10 papers). Martin Hoyle is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Pharmaceutical Economics and Policy (10 papers). Martin Hoyle collaborates with scholars based in United Kingdom, Australia and United States. Martin Hoyle's co-authors include William Henley, T Moxham, Rob Anderson, Ken Stein, Mark Bond, James Cresswell, G Rogers, Chris Cooper, Christopher Hyde and Tracey Jones-Hughes and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Infectious Diseases and Proceedings of the Royal Society B Biological Sciences.

In The Last Decade

Martin Hoyle

65 papers receiving 2.2k citations

Peers

Countries citing papers authored by Martin Hoyle

Since Specialization

Citations

This map shows the geographic impact of Martin Hoyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Hoyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Hoyle more than expected).

Fields of papers citing papers by Martin Hoyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Hoyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Hoyle. The network helps show where Martin Hoyle may publish in the future.

Co-authorship network of co-authors of Martin Hoyle

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Hoyle. A scholar is included among the top collaborators of Martin Hoyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Hoyle. Martin Hoyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee 2024 ·PharmacoEconomics ·(unknown), A. R. Norman, Martin Hoyle, Sean Lybrand, Bonny Parkinson	2
2	Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia 2022 ·PharmacoEconomics ·(unknown), Varinder Jeet, Rajan Sharma, Martin Hoyle, Bonny Parkinson	18
3	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation 2021 ·Health Technology Assessment ·Irina A. Tikhonova, Huiqin Yang, (unknown), Andrew Salmon, Sophie Robinson, Mohsen Rezaei Hemami‬, (unknown), (unknown), Richard Haigh, Meghna Jani, Timothy J. McDonald, Martin Hoyle	7
4	PRS50 BENRALIZUMAB FOR TREATING SEVERE EOSINOPHILIC ASTHMA: NICE SINGLE TECHNOLOGY APPRAISAL 2019 ·Value in Health ·Irina A. Tikhonova, Linda Long, (unknown), Maxwell S. Barnish, Siân Robinson, (unknown), (unknown), (unknown), Martin Hoyle	1
5	The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation 2017 ·Health Technology Assessment ·Nicola Huxley, Louise Crathorne, Jo Varley‐Campbell, Irina A. Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier, Martin Hoyle	33
6	Cost Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorecal Cancer 2016 ·Value in Health ·Irina A. Tikhonova, Martin Hoyle, Tristan Snowsill, Louise Crathorne, (unknown), Jaime Peters, Simon Briscoe, Mark Bond, Nicola Huxley	1
7	Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal 2016 ·PharmacoEconomics ·Irina A. Tikhonova, Martin Hoyle, Tristan Snowsill, Chris Cooper, (unknown), Claudius Rudin, Rubén Mújica-Mota	6
8	A model-based assessment of the cost–utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients 2015 ·BMC Cancer ·Tristan Snowsill, Nicola Huxley, Martin Hoyle, Tracey Jones-Hughes, Helen Coelho, Chris Cooper, Ian M. Frayling, Chris Hyde	35
9	Model-Based Cost–Utility Analysis of Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Treatment Induced Anaemia in the UK NHS 2014 ·Value in Health ·Tristan Snowsill, Nicola Huxley, Martin Hoyle, Louise Crathorne, Marcela Haasova, Simon Briscoe, Helen Coelho, Antonieta Medina‐Lara, (unknown), Mark Napier, Christopher Hyde	1
10	When It May Not Be Necessary To Model Overall Survival for Economic Evaluations of Anti-Cancer Drugs 2014 ·Value in Health ·Martin Hoyle, William Hamilton, Charles M. Rudin	1
11	The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model 2013 ·Health Technology Assessment ·Martin Hoyle, Louise Crathorne, Jaime Peters, Tracey Jones-Hughes, Chris Cooper, Mark Napier, Paul Tappenden, Christopher Hyde	63
12	Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence 2013 ·Value in Health ·Oriana Ciani, Martin Hoyle, Toby Pavey, Chris Cooper, (unknown), (unknown), (unknown)	22
13	Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer 2013 ·Value in Health ·Martin Hoyle, Jaime Peters, Louise Crathorne, Tracey Jones-Hughes, Chris Cooper, Mark Napier, Chris Hyde	37
14	Improved curve fits to summary survival data: application to economic evaluation of health technologies 2011 ·BMC Medical Research Methodology ·Martin Hoyle, William Henley	250
15	Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis 2010 ·PharmacoEconomics ·Martin Hoyle	45
16	The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model 2009 ·Health Technology Assessment ·Mark Bond, Stuart Mealing, Rob Anderson, Julian Elston, Graeme M. Weiner, RS Taylor, Martin Hoyle, (unknown), Alison Price, Ken Stein	239
17	Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness 2009 ·British Journal of Cancer ·(unknown), (unknown), Martin Hoyle, G Rogers, C Green, T Moxham, Karen Welch, Ken Stein	50
18	THE EFFECT OF WIND DIRECTION ON CROSS-POLLINATION IN WIND-POLLINATED GM CROPS 2007 ·Ecological Applications ·Martin Hoyle, James Cresswell	38
19	A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow 2007 ·Journal of Theoretical Biology ·Martin Hoyle, James Cresswell	8
20	Cytokine response profiles predict species-specific infection patterns in human GI nematodes 2004 ·International Journal for Parasitology ·Joseph A. Jackson, Joseph D. Turner, (unknown), Helen Faulkner, J.M. Behnke, Martin Hoyle, Richard K. Grencis, Kathryn J. Else, Joseph Kamgno, Janette E. Bradley, Michel Boussinesq	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact